About Intox Private Limited
Data last updated:
Intox Private Limited is a private limited company based in Mulshi, Maharashtra, India, a subsidiary of Aragen Life Sciences Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 17 July 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U74999PN2000PTC015116. Its GSTIN is 27AAACI9605G1ZL (Maharashtra).
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹76 Lakh. It is led by directors including Mukul Prabhakar Pore and Ajay Srivastava.
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Gat Nos. 367 373 375 And 376, Mulshi, Maharashtra, India – 412115.
As per the financials filed for FY 2025, the company reported a revenue of ₹45.44 Cr, a decline of 20% compared to the previous year. For the same year it recorded a net profit of ₹5.88 Cr (net margin 12.9%) and EBITDA of ₹11.83 Cr (EBITDA margin 26%). Revenue has grown at a compounded annual rate (CAGR) of 12% over three years and 13% over five years.
The company has about 118 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: INTOX lab. As per MCA filings, the company has satisfied charges of ₹2.91 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website intoxlab.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressGat Nos. 367 373 375 And 376, Mulshi, Maharashtra, India – 412115
- IndustryPharma, Pharma Contract R&D
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Intox Private Limited
The main business activity of Intox is professional, scientific and technical. In detail, this covers architecture, engineering activities, technical testing and analysis activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M4 | Architecture, engineering activities, technical testing and analysis activities | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Intox Private Limited FY 2025 filings available
Intox Private Limited reported revenue of ₹45.44 Cr (down 20% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Intox Private Limited
Revenue fell 20% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 13%. EBITDA fell 17% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Intox Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹11.83 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹5.88 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Intox Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 26% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 12.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Intox are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Intox Private Limited
Intox Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Contract Research). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Allucent (India) Private Limited | ₹47.87 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | Bangalore, Karnataka, India |
| Jeevan Scientific Technology Limited Listed | ₹47.5 Cr (FY 2025) | •••• | •••• | 18.0% | •••• | Hyderabad, Telangana, India |
| Emerald Clinical Trials India Private Limited | ₹46.42 Cr (FY 2025) | •••• | •••• | -28.0% | •••• | Bangalore, Karnataka, India |
| Premas Biotech Private Limited | ₹45.93 Cr (FY 2025) | •••• | •••• | 65.0% | •••• | Manesar, Haryana, India |
| Vivo Bio Tech Limited Listed | ₹45.49 Cr (FY 2024) | •••• | •••• | -13.0% | •••• | Hyderabad, Telangana, India |
| Intox Private Limited this company | ₹45.44 Cr (FY 2025) | •••• | •••• | -20.0% | •••• | Mulshi, Maharashtra, India |
| Shubham Specialty Products (India) Private Limited | ₹45.42 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Mumbai, Maharashtra, India |
| Raghava Life Sciences Private Limited | ₹45.14 Cr (FY 2025) | •••• | •••• | -26.0% | •••• | Hyderabad, Telangana, India |
| Clinigene International Limited | ₹44.41 Cr (FY 2014) | •••• | •••• | •••• | Bangalore, Karnataka, India | |
| Scitus Pharma Services Private Limited | ₹43.45 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Chennai, Tamil Nadu, India |
| Invitron Advanced Analytics Private Limited | ₹43.29 Cr (FY 2025) | •••• | •••• | 45.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Intox by revenue in the Pharma industry (Contract Research), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Intox Private Limited
Intox Private Limited is audited by Kirtane & Pandit LLP for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Kirtane & Pandit LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Intox Private Limited
Intox has 4 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mukul Prabhakar Pore Also directs: Toxgurukul Foundation | Director | 09 Dec 2022 | 3 Years 10 Months | Current |
| Ajay Srivastava | Director | 13 Dec 2021 | 4 Years 9 Months | Current |
| Narendra Sampatrao Deshmukh | Director | 15 Dec 2023 | 2 Years 9 Months | Current |
| Manmahesh Kantipudi Also directs: Aragen Life Sciences Limited, Aragen Biologics Private Limited, Zeroharm Sciences Private Limited and 2 more | Director | 25 Apr 2023 | 3 Years 5 Months | Current |
Ownership and Shareholding of Intox Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Intox Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jul 2020 | Others | ₹59,000 | Satisfied |
| 21 Dec 2015 | Others | ₹2.2 Cr | Satisfied |
| 04 Mar 2003 | The Saraswat Co-Operative Bank Limited | ₹70 Lakh | Satisfied |
Total charge records: 3 View all charges
Legal Cases of Intox Private Limited
Intox Private Limited has 2 court cases on record: 2 filed by Intox. All cases are disposed. Status as checked on 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 0 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (CAW) | Filed by the company against an individual | Disposed |
| Bombay High Court | Writ petition | Filed by the company against an individual | Disposed |
Full case history
All 2 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Intox Private Limited
Intox Private Limited has 8 MSME Form 1 returns on record between 2021 and 2024, listing 803 overdue payments to 92 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 92)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Skyward Telecom Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 8 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Intox Private Limited
Intox operates one associated brand: INTOX lab. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Preclinical contract research services in toxicology are offered. | intoxlab.com |
Employees and EPFO Compliance at Intox Private Limited
Intox Private Limited has a workforce of 118 employees as of Apr 02, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Intox Private Limited
Intox Private Limited has 10 board changes on record since 2019: 4 appointments and 6 cessations. The latest: Narendra Sampatrao Deshmukh was appointed as Director on 15 Dec 2023.
8 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Intox Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Intox Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Intox Private Limited
Intox has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACI9605G1ZL | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Intox Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intox Private Limited
Intox is an active private limited company based in Mulshi, Maharashtra, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 17 July 2000 (26+ years old) and is registered under CIN U74999PN2000PTC015116.
Intox reported revenue of ₹45.44 Cr for FY 2025 (down 20% YoY).
Intox has 4 current directors:
- Mukul Prabhakar Pore - Director
- Ajay Srivastava - Director
- Narendra Sampatrao Deshmukh - Director
- Manmahesh Kantipudi - Director
Intox reported a net profit of ₹5.88 Cr (net margin 12.9%) and EBITDA of ₹11.83 Cr (EBITDA margin 26%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Intox is -12% over three years and 13% over five years. In the latest year (FY 2025) revenue fell 20%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Intox is 27AAACI9605G1ZL, registered in Maharashtra.
The CIN (Corporate Identification Number) of Intox is U74999PN2000PTC015116. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Intox has 2 court cases on record: 2 filed by the company.
Intox was incorporated on 17 July 2000, making it 26+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Intox by revenue are Allucent (India) Private Limited, Jeevan Scientific Technology Limited, Emerald Clinical Trials India Private Limited, Premas Biotech Private Limited, Vivo Bio Tech Limited and 5 more, all in the Pharma industry (Contract Research).
Narendra Sampatrao Deshmukh was appointed as Director on 15 Dec 2023. Manmahesh Kantipudi ceased to be Additional Director on 06 Jun 2023. Manmahesh Kantipudi was appointed as Director on 25 Apr 2023. Intox has 10 board changes on record in total.
Intox has 8 MSME Form 1 returns on record between 2021 and 2024, listing 803 overdue payments to 92 micro and small suppliers. The latest return was filed on 01 May 2024.